Literature DB >> 20349294

[GLP-1: a new therapeutic principle for the treatment of type 2 diabetes mellitus].

Björn A Menge1, Juris J Meier, Wolfgang E Schmidt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20349294     DOI： 10.1007/s00063-010-1026-6

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN： 0723-5003


× No keyword cloud information.
  40 in total

1.  Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.

Authors:  Dennis Kim; Leigh MacConell; Dongliang Zhuang; Prajakti A Kothare; Michael Trautmann; Mark Fineman; Kristin Taylor
Journal:  Diabetes Care       Date:  2007-03-12       Impact factor: 19.112

Review 2.  The incretin concept today.

Authors:  W Creutzfeldt
Journal:  Diabetologia       Date:  1979-02       Impact factor: 10.122

Review 3.  Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides.

Authors:  R Mentlein
Journal:  Regul Pept       Date:  1999-11-30

4.  Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects.

Authors:  Juris J Meier; Baptist Gallwitz; Bartholomaeus Kask; Carolyn F Deacon; Jens J Holst; Wolfgang E Schmidt; Michael A Nauck
Journal:  Diabetes       Date:  2004-12       Impact factor: 9.461

5.  Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

Authors:  Ralph A DeFronzo; Robert E Ratner; Jenny Han; Dennis D Kim; Mark S Fineman; Alain D Baron
Journal:  Diabetes Care       Date:  2005-05       Impact factor: 19.112

6.  Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.

Authors:  Michael A Nauck; Andrea El-Ouaghlidi; Bartholomäus Gabrys; Katrin Hücking; Jens J Holst; Carolyn F Deacon; Baptist Gallwitz; Wolfgang E Schmidt; Juris J Meier
Journal:  Regul Pept       Date:  2004-11-15

7.  Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes.

Authors:  Jessica E Matthews; Murray W Stewart; Erika H De Boever; Robert L Dobbins; Rebecca J Hodge; Susan E Walker; M Claire Holland; Mark A Bush
Journal:  J Clin Endocrinol Metab       Date:  2008-09-23       Impact factor: 5.958

8.  Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.

Authors:  Juris J Meier; Baptist Gallwitz; Stefan Salmen; Oliver Goetze; Jens J Holst; Wolfgang E Schmidt; Michael A Nauck
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

9.  Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships.

Authors:  R Ritzel; C Orskov; J J Holst; M A Nauck
Journal:  Diabetologia       Date:  1995-06       Impact factor: 10.122

10.  The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone.

Authors:  Ralph A DeFronzo; Miguel N Hissa; Alan J Garber; Jorge Luiz Gross; Raina Yuyan Duan; Shoba Ravichandran; Roland S Chen
Journal:  Diabetes Care       Date:  2009-05-28       Impact factor: 19.112
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.